Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 94,318 |
|
|||||
| News | - | ||||||
| Day High | 1.47 | Low High |
|||||
| Day Low | 1.37 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CERo Therapeutics Holdings Inc | CERO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.09 | -6.38% | 1.32 | 23:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.42 | 1.37 | 1.47 | 1.37 | 1.41 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 514 | 94,318 | US$ 1.41 | US$ 132,565 | - | 1.33 - 12.38 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:57:49 | 16 | US$ 1.38 | USD |
CERo Therapeutics Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 19.44M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CERo Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/07/2024 | 06:00 | Business Wire | CERo Therapeutics, Inc. Announces Publication of Preclinical.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CERO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.52 | 1.5799 | 1.33 | 1.43 | 122,553 | -0.20 | -13.16% |
| 1 Month | 2.92 | 3.76 | 1.33 | 2.39 | 494,362 | -1.60 | -54.79% |
| 3 Months | 5.25 | 12.38 | 1.33 | 3.10 | 1,375,040 | -3.93 | -74.86% |
| 6 Months | 5.25 | 12.38 | 1.33 | 3.10 | 1,375,040 | -3.93 | -74.86% |
| 1 Year | 5.25 | 12.38 | 1.33 | 3.10 | 1,375,040 | -3.93 | -74.86% |
| 3 Years | 5.25 | 12.38 | 1.33 | 3.10 | 1,375,040 | -3.93 | -74.86% |
| 5 Years | 5.25 | 12.38 | 1.33 | 3.10 | 1,375,040 | -3.93 | -74.86% |
CERo Therapeutics Description
| CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company¿s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body¿s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies. |
